In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other safe stocks. Hedge funds, known for their sophisticated investment strategies and ...

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

It is the largest study ever of the drug category—which includes Novo Nordisk’s GLP-1 treatments Ozempic and Wegovy and Eli Lilly’s dual-action GLP-1/GIP agonists Mounjaro and Zepbound.

Eli Lilly's Q4 FY24 guidance adjustment is due to supply chain factors, not demand, creating an attractive buying opportunity with a 'Buy' rating. Despite a modest 0.6% revenue reduction ...

The company is headquartered in Indianapolis, Indiana. Read More on LLY: Eli Lilly NewsMORE Related Stocks Indices Commodities ...

In this article, we are going to take a look at where Eli Lilly And Co. (NYSE:LLY) stands against other stocks that could split in the near future. Stock splits don’t change how much a company ...

Lepodisiran sodium is under clinical development by Eli Lilly and Co and currently in Phase ... Africa and Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US. For a complete picture ...

Eli Lilly recently updated Q4 revenue guidance, and sales are expected to come in lower than previously anticipated. While this could suggest the company is experiencing sluggish or plateauing ...

Eli Lilly and Company (NYSE:LLY) will increase its dividend from last year's comparable payment on the 10th of March to $1.50. This takes the annual payment to 0.8% of the current stock price ...